Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases. 2017

Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey.

Human carbonic anhydrases IX and XII are upregulated in many tumors and form a novel target for new generation anticancer drugs. Here we report the synthesis of novel 2-indolinone derivatives with the sulfonamide group as a zinc binding moiety. Enzyme inhibition assays confirmed that the compounds showed selectivity against hCA IX and XII over the widely distributed off-targets hCA I and II. Molecular modelling studies were performed to suggest modes of binding for these compounds.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D002256 Carbonic Anhydrases A family of zinc-containing enzymes that catalyze the reversible hydration of carbon dioxide. They play an important role in the transport of CARBON DIOXIDE from the tissues to the LUNG. EC 4.2.1.1. Carbonate Dehydratase,Carbonic Anhydrase,Anhydrases, Carbonic,Dehydratase, Carbonate
D002257 Carbonic Anhydrase Inhibitors A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. Carbonate Dehydratase Inhibitor,Carbonate Dehydratase Inhibitors,Carbonic Anhydrase Inhibitor,Carboxyanhydrase Inhibitor,Carboxyanhydrase Inhibitors,Anhydrase Inhibitor, Carbonic,Dehydratase Inhibitor, Carbonate,Inhibitor, Carbonate Dehydratase,Inhibitor, Carbonic Anhydrase,Inhibitor, Carboxyanhydrase,Inhibitors, Carbonate Dehydratase,Inhibitors, Carbonic Anhydrase,Inhibitors, Carboxyanhydrase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071231 Carbonic Anhydrase IX A carbonic anhydrase and transmembrane protein that consists of an N-terminal PROTEOGLYCAN-like domain, a catalytic region, a single-pass transmembrane domain, and a short intracellular tail. It functions as a dimer and is expressed primarily by cells of the GASTROINTESTINAL TRACT; BILE DUCT EPITHELIUM; and GALL BLADDER. It is expressed at high levels in many solid tumors, especially CLEAR CELL RENAL CARCINOMA, in response to CELL HYPOXIA. CAIX Protein,Carbonic Anhydrase 9
D000078183 Oxindoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl and a carbonyl at the pyrrole ring typically at the 2-position. Ajmalicine Oxindole,Ajmalicine Oxindoles,Ajmalicine-Type Oxindole,Ajmalicine-Type Oxindoles,Indolinone,Indolinone Derivative,Macroline Oxindole,Macroline Oxindoles,Macroline-Type Oxindole,Macroline-Type Oxindoles,Oxazolidinone Derivative,Oxindole Alkaloid,Oxindole Alkaloid Derivative,Oxindole Derivative,Indolinone Derivatives,Indolinones,Oxazolidinone Derivatives,Oxindole Alkaloid Derivatives,Oxindole Alkaloids,Oxindole Derivatives,Ajmalicine Type Oxindole,Ajmalicine Type Oxindoles,Alkaloid Derivative, Oxindole,Alkaloid, Oxindole,Derivative, Indolinone,Derivative, Oxazolidinone,Derivative, Oxindole,Derivative, Oxindole Alkaloid,Macroline Type Oxindole,Macroline Type Oxindoles,Oxindole, Ajmalicine,Oxindole, Ajmalicine-Type,Oxindole, Macroline,Oxindole, Macroline-Type,Oxindoles, Ajmalicine,Oxindoles, Ajmalicine-Type,Oxindoles, Macroline,Oxindoles, Macroline-Type
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
July 2017, Bioorganic & medicinal chemistry,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
January 2014, BioMed research international,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
March 2013, Bioorganic & medicinal chemistry,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
February 2024, Bioorganic chemistry,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
March 2019, International journal of molecular sciences,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
January 2006, Advances in clinical chemistry,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
April 2022, Amino acids,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
December 2000, Cancer research,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
December 2020, Journal of enzyme inhibition and medicinal chemistry,
Nilgün Karalı, and Atilla Akdemir, and Füsun Göktaş, and Pınar Eraslan Elma, and Andrea Angeli, and Merih Kızılırmak, and Claudiu T Supuran
April 2012, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!